TALL 104
Alternative Names: ABIO-05/01; ABIO-0501; Human MHC non-restricted cytotoxic T-cell line - Galileo Research; TALL-104Latest Information Update: 26 May 2023
Price :
$50 *
At a glance
- Originator Wistar Institute
- Developer Abiogen Pharma; Galileo Research; University of Texas M. D. Anderson Cancer Center
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Ovarian cancer
- No development reported Peritoneal cancer
- Discontinued Chronic myeloid leukaemia
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 19 Feb 2021 TALL 104 is still in phase II trial for Ovarian cancer (Late-stage disease, Metastatic disease) in Italy (Intraperitoneal) (EudraCT2013-001005-82)
- 29 Jul 2015 No recent reports on development identified - Phase-I/II for Peritoneal cancer in Italy (IV & Intraperitoneal)